Form 4: GeneDx Holdings CEO Sells Shares Under Pre-Arranged Trading Plan

GeneDx Holdings Corp. CEO Katherine Stueland sold a total of 9,657 shares of Class A Common Stock on July 1, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp. (WGS), reported the sale of Class A Common Stock.
• The transactions occurred on July 1, 2025.
• A total of 9,657 shares were sold across three separate transactions.
• The shares were sold at weighted average prices of $90.6777, $91.551, and $92.4609 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Katherine Stueland on August 16, 2024.
• Following these reported transactions, Katherine Stueland beneficially owns 4,940 shares of Class A Common Stock.

Sentiment

Score: 4

Explanation: The filing reports an insider sale of shares, which can sometimes be perceived negatively, though the sale was pre-scheduled under a Rule 10b5-1 plan, mitigating immediate negative implications.

Negatives

• Reduction in insider ownership by 9,657 shares, which could be perceived negatively by some investors, despite being part of a pre-arranged plan.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Management Comments

• The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Katherine Stueland on August 16, 2024.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may interpret the sale of shares by the Chief Executive Officer as a signal, although the pre-arranged 10b5-1 plan indicates a planned transaction rather than a reaction to new information.

Key Dates

Keywords

GeneDx Holdings Corp., WGS, Form 4, insider trading, stock sale, CEO, Katherine Stueland, 10b5-1 plan, Class A Common Stock